ARTICLE

Received 29 Aug 2014 | Accepted 28 Nov 2014 | Published 9 Jan 2015

DOI: 10.1038/ncomms6987

OPEN

BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells

Walid T. Khaled^{1,2,*}, Song Choon Lee^{1,*}, John Stingl³, Xiongfeng Chen⁴, H. Raza Ali^{3,5}, Oscar M. Rueda³, Fazal Hadi², Juexuan Wang¹, Yong Yu¹, Suet-Feung Chin³, Mike Stratton¹, Andy Futreal¹, Nancy A. Jenkins⁶, Sam Aparicio⁷, Neal G. Copeland⁶, Christine J. Watson⁸, Carlos Caldas^{3,5,9} & Pentao Liu¹

Triple-negative breast cancer (TNBC) has poor prognostic outcome compared with other types of breast cancer. The molecular and cellular mechanisms underlying TNBC pathology are not fully understood. Here, we report that the transcription factor *BCL11A* is overexpressed in TNBC including basal-like breast cancer (BLBC) and that its genomic locus is amplified in up to 38% of BLBC tumours. Exogenous *BCL11A* overexpression promotes tumour formation, whereas its knockdown in TNBC cell lines suppresses their tumourigenic potential in xenograft models. In the DMBA-induced tumour model, *Bcl11a* deletion substantially decreases tumour formation, even in p53-null cells and inactivation of *Bcl11a* in established tumours causes their regression. At the cellular level, *Bcl11a* deletion causes a reduction in the number of mammary epithelial stem and progenitor cells. Thus, *BCL11A* has an important role in TNBC and normal mammary epithelial cells. This study highlights the importance of further investigation of *BCL11A* in TNBC-targeted therapies.

¹ Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1HH, UK. ² Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK. ³ Cancer Research UK Cambridge Institute, and Department of Oncology, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK. ⁴ SAIC-Frederic, National Cancer Institute-Frederick, Frederick, Maryland 21701, USA. ⁵ Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0RE, UK. ⁶ The Methodist Hospital Research Institute, 6670 Bertner Street, Houston, Texas 77030, USA. ⁷ Molecular Oncology Department, BC Cancer Agency Research Centre, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. ⁸ Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK. ⁹ Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 2QQ, UK. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to W.T.K. (email: wtk22@cam.ac.uk) or to P.L. (email: pl2@sanger.ac.uk).

One of the major challenges in treating breast cancer is the heterogeneous nature of the disease¹. TNBC accounts for around 15% of all breast cancer cases and in the absence of effective targeted therapies, TNBC patients tend to have a poor prognosis^{2–4}. At the molecular level, several distinct subtypes of breast cancer have been identified based on the gene expression profiling^{3,5,6}. The most commonly used classification describes six subtypes: luminal A, luminal B, Her2, claudin low, basal-like breast cancer (BLBC) and normal^{3,6}. More recently, analysis of large numbers of tumour samples as part of the METABRIC study identified 10 pathologically distinct subtypes known as integrative cluster (IC) 1–10 (ref. 5). The majority of TNBC cases (80%) have a BLBC⁷ or IC10 (ref. 5) gene expression signatures. In addition, cancer sequencing studies have identified mutations of *p53*, *PTEN* and *BRCA1* in TNBC^{2,4,8,9}. However, driver oncogenic genomic aberrations in TNBC have not been comprehensively identified.

The developmental hierarchies of the mammary epithelium and hematopoietic lineages share many similarities¹⁰ in that stem cells progressively give rise to lineage-restricted progenitors, which ultimately differentiate and generate all functional cells. A number of key hematopoiesis transcription factors have important roles in mouse mammary gland development and are human breast cancer genes^{11–15}. For example, the key regulator of T-helper-2 cell development, *GATA3*, is critical in luminal mammary cell development^{12,13} and is a luminal breast cancer marker gene¹⁶. In this study we interrogated cancer genomics data focusing on a subset of important hematopoiesis factors and identified *BCL11A* as a novel TNBC oncogene.

Results

***BCL11A* is highly expressed in triple-negative breast cancer.** In an attempt to identify potential TNBC oncogenes, we selected a list of genes known to have important roles in hematopoiesis and investigated their expression across the major molecular

subtypes of breast cancer³. We first re-analysed a publically available microarray data set⁶ and found that out of the examined genes, *BCL11A* was differentially and highly expressed in BLBC (Supplementary Fig. 1a). This is in sharp contrast to *GATA3*, which is highly expressed only in luminal subtypes (Supplementary Fig. 1a) and is a known prognostic marker for these tumours¹⁶.

We then investigated the expression of *BCL11A* in other patient data sets including METABRIC⁵ and TCGA⁸, which between them have curated gene expression, copy number (CN) variation and clinical data from close to 3,000 patients⁵. Pathologically, we found that high *BCL11A* expression significantly correlated with TNBC pathology (Fig. 1a). At the molecular level, high *BCL11A* expression was also found to significantly correlate with the BLBC subtype in the METABRIC, TCGA and six other microarray data sets (Fig. 1b and Supplementary Fig. 1b). Quantitative reverse transcription PCR (qRT-PCR) analysis of *BCL11A* expression on a randomly selected subset of METABRIC tumours (all subtypes, $n = 230$) validated the above expression data (Supplementary Fig. 2a). In addition, we also found that high *BCL11A* expression in METABRIC samples correlated with the recently described IC10 cluster of tumours (Fig. 1c), thus further supporting the concordance between the BLBC and IC10 classifications. Consistent with TNBC cases, high *BCL11A* expression was significantly correlated with a high histological grade (Supplementary Fig. 2b).

Furthermore, high *BCL11A* expression in BLBC cases was further validated by immunohistochemistry (IHC) on a subset of the METABRIC tumours (all subtypes, $n = 368$. BLBC, $n = 24$). Strong *BCL11A* immunostaining was predominantly found in BLBC (Fig. 2a). Out of 24 BLBC samples examined from this subset, 16 scored positive for *BCL11A* (Fig. 2a; details in Methods). In addition, samples stained positively in IHC also had higher RNA levels compared with those scored as negative (Supplementary Fig. 2c).

Figure 1 | *BCL11A* is highly expressed in TNBC. (a) Significant correlation between *BCL11A* expression and the TNBC type of breast cancer in both METABRIC ($n = 2,000$) and TCGA ($n = 1,100$) data sets—* indicates t -test P value < 0.005 . (b) *BCL11A* expression across the six molecular subtypes of breast cancer ('Normal' refers to the PAM50 subtype) in both METABRIC and TCGA data sets—* indicates t -test P value < 0.005 . (c) The METABRIC samples distributed according to the ICs 1–10, showing the correlation between *BCL11A* expression and IC10—* indicates t -test P value < 0.005 .

Figure 2 | Genomic alterations at the *BCL11A* locus. (a) Images and scoring of BCL11A IHC staining on a subset of tumours from the METABRIC study (see Methods for scoring)—* indicated χ^2 -test $P < 0.0001$. (b–d) Bar chart depicting the percentage of samples that harbour *BCL11A* CN gains in each subtype in both METABRIC and TCGA data sets—* indicates χ^2 -test $P < 0.0001$. (e) Scatter plots showing the methylation status of the *BCL11A* locus in all tumours or basal only from the TCGA data set. The colour-coded legend indicated the *BCL11A* CN status for each tumour. (f–g) Kaplan-Meier plots showing the survival rate comparison between patients who have normal or high levels of *BCL11A* expression, or between patients with CN gains or without (neutral).

One mechanism for the induction of high *BCL11A* expression in BLBC cases could be CN aberrations. From ~2,000 breast cancer cases in METABRIC⁵, CN gains at the *BCL11A* genomic locus were identified in 62 patients (Supplementary Fig. 3a), which also correlates with high *BCL11A* expression (Supplementary Fig. 3b). Importantly, out of these 62 patients with CN gains, 39 were classified as BLBC, which account for 18.6% (39/210) of the total BLBC cases in METABRIC (Fig. 2b). Examination of the TCGA data set revealed that 38% (31/81) of BLBC samples have *BCL11A* CN gains, which is again significantly correlated with higher gene expression (Fig. 2c and Supplementary Fig. 3c). A similar result was also found when the METABRIC data was analysed using the integrative clustering, with 15.6% of IC10 samples having *BCL11A* CN gains (Fig. 2d).

Further analysis of the TCGA data set revealed that in BLBCs, the *BCL11A* locus is almost exclusively hypomethylated and this is correlated with high expression levels (Fig. 2e). There was also no correlation between *BCL11A* CNs and the methylation status. This result suggests that epigenetic changes at the *BCL11A* locus could be another mechanism that contributes to its high expression in BLBC. Given the strong correlation with TNBC, patients with either high expression or CN gains of *BCL11A* had poor survival rates compared with the rest of the cohort (Fig. 2f, g). A similar trend was also observed in four other patient data sets^{17–20} (Supplementary Fig. 3 f–i). In particular, patients with CN gains of *BCL11A* had a higher rate of relapse and metastasis and a lower rate of survival (Supplementary Fig. 3d–e). The utility of *BCL11A* expression/CN as a biomarker in the clinic thus warrants further investigation. Indeed, the future release of

patient outcome for the complete TCGA cohort will aid in clarifying this finding.

High levels of *BCL11A* promote tumour development.

Although *BCL11A* is involved in rare B-cell lymphomas and is able to transform fibroblast cells *in vitro*^{21,22}, the cellular and molecular mechanisms of *BCL11A*-mediated tumourigenesis remains unclear. To address this, we first tested whether *BCL11A* overexpression could promote the colony formation or tumour development in mammary epithelial cells. We overexpressed *BCL11A* in immortalized non-tumourigenic mouse Eph4 (ref. 23) or human HMLE^{24,25} cells (Supplementary Fig. 4a) and performed Matrigel and suspension mammosphere assays. Forced *BCL11A* expression in both Eph4 and HMLE (Eph4-11A and HMLE-11A) cells resulted in double the number of spheres compared with their respective control cells (Fig. 3a–b). Furthermore, mouse Eph4-11A cells injected orthotopically in cleared mammary fat pads of immune-compromized *NOD/SCID/IL2 γ ^{-/-}* (NSG) mice²⁶ formed larger and palpable tumours compared with control cells ($n=6$) (Fig. 3c and Supplementary Fig. 4b). Similarly, three out of four mice injected with HMLE-11A cells developed tumours within 8 weeks of injection (Fig. 3d and Supplementary Fig. 4c) suggesting that elevated levels of *BCL11A* promote tumour development. Moreover, gene expression analysis of these three tumours along with the 2,000 tumours from the METABRIC study clustered them with the BLBC subgroup (Fig. 3e).

Knockdown of *BCL11A* reduces tumourigenicity of TNBC cells. Analysis of *BCL11A* expression in a panel of breast cancer cell lines revealed that *BCL11A* is highly expressed in TNBC lines

but is undetectable in any of the luminal cell lines tested (Supplementary Fig. 5a). Next, we assessed if disrupting *BCL11A* expression could affect the clonogenic and oncogenic potential of the TNBC cell lines. To inactivate *BCL11A* in these cells, we performed shRNA knockdown experiments (Supplementary Fig. 5b) in the TNBC cell lines 4T1 (mouse), MDA231, SUM159 and HMLER (human). Knockdown of *BCL11A* had no significant impact on cell viability, cell cycle kinetics or cell death (Fig. 4a–c and Supplementary Fig. 5b,d). However, *BCL11A* knockdown significantly reduced the clonogenic capacity of all four cell lines (Fig. 4d–f and Supplementary Fig. 5c). To assess tumourigenic potential, *BCL11A* knockdown cells were injected subcutaneously into NSG recipients. Robust tumours developed from the control 4T1, MDA231, SUM159 and HMLER cells within 25 days. In contrast, the *BCL11A* knockdown cells produced tumours of significantly reduced sizes (Fig. 4g–i and Supplementary Fig. 5c). Furthermore, primary and secondary limiting dilution transplantations of MDA231 control or shRNA1 cells revealed a reduction in the number of tumour-initiating cells during the secondary transplants from 1/123 to 1/667 (Supplementary Fig. 5e).

***Bcl11a* is required for the development of DMBA tumours.** To examine the role of *BCL11A* in mammary tumour development *in vivo*, we generated *Bcl11a* conditional knockout (cko) mice (referred to as *flox/flox*; Supplementary Fig. 6a), as germline deletion of *Bcl11a* causes neonatal lethality²⁷ and crossed them to the inducible *Rosa26-CreERT2*. As a tumour model, we used the potent carcinogen DMBA (7,12-dimethylbenz(a)anthracene) in combination with medroxyprogesterone acetate (MPA) to promote TNBC-like tumours in the mouse^{28,29}. To minimize the effects of *Bcl11a* deletion on non-mammary tissues, we

Figure 3 | High levels of *BCL11A* enhance clonogenicity of mammary epithelial cells and promote tumourigenesis. (a) Comparison of colony numbers in matrigel from Eph4-11A cells or from the control cells. Data are presented as mean $\pm$ s.d. ($n=3$). Image on the right are depicting Eph4-control and Eph4-11A mammospheres grown in Matrigel (scale bar, 100 μ m). P value indicates student's t -test. (b) Comparison of the number of floating mammospheres formed from human HMLE-11A cells or the control cells. Data are presented as mean $\pm$ s.d. ($n=3$). Images on the right are of floating mammospheres formed by HMLE-control and HMLE-11A-expressing cell (scale bar, 200 μ m). P value indicates student's t -test. (c) Graph depicting the size difference between tumours at 6 weeks after injection of Eph4-control and Eph4-11A cells orthotopically into contralateral mammary fat pads. Data are presented as mean $\pm$ s.d. ($n=6$). P value indicates student's t -test. (d) Kaplan-Meier survival curve depicting the percentage of tumour-free mice injected with either HMLE-control or HMLE-11A cells ($n=4$). (e) Unsupervised clustering of the HMLE-11A tumours in the mouse with human tumours from the METABRIC study based on the PAM50 (ref. 3) gene expression. Nearest centroid correlation score is plotted against the various subtypes for all three tumours.

Figure 4 | *BCL11A* knockdown in TNBC cells reduces tumour development. (a) Western blot showing *BCL11A* knockdown efficiency in 4T1, SUM159 and MDA231 cells transfected with control (scramble), shRNA1 or shRNA2 vectors. (b) MTS cell viability assay (see Methods) shows that *BCL11A* knockdown does not affect cell viability in culture. (c) EdU cell cycle analysis showing that *Bcl11a* knockdown does not affect cell cycle kinetics in all tested cell lines. Data are presented as mean $\pm$ s.d. (n = 3). (d-f) Comparison of colony numbers from control, shRNA1 and shRNA2 in 4T1, SUM159 and MDA231 cells. Data are presented as mean $\pm$ s.d. (n = 3). *P* value indicates student's *t*-test. (g-i) Graph depicting the reduction in tumour size observed when shRNA1 or shRNA 2 transfected 4T1, SUM159 or MDA231 cells are injected subcutaneously into mice compared with control. Image under graph shows the actual tumours measured (scale bar, 5 mm). Unpaired *T*-test was performed on d-i and * indicates $P < 0.05$ and ** indicates $P < 0.005$.

transplanted mammary tissue from 8- to 12-week-old control (wild type) or *flox/flox* virgin female mice into contralateral cleared fat pads of female NSG mice followed by DMBA mutagenesis as illustrated in Supplementary Fig. 6b. By week 15, after the last dose of DMBA was administered, palpable tumours were visible in the mammary glands engrafted with the control mammary cells, but not with the *flox/flox* cells (Fig. 5a). By week 22 post DMBA treatment, all control cell engraftments (8/8) developed tumours compared with only one from *flox/flox* mammary cells (1/8) (Fig. 5b). qRT-PCR analysis of this tumour revealed expression of *Bcl11a* probably owing to incomplete

Cre-*loxP* recombination (Supplementary Fig. 6c, sample T1). Also, qRT-PCR and IHC results revealed that tumours upregulated *Bcl11a* expression in response to DMBA-induced carcinogenesis (Supplementary Fig. 6c-d). These data thus reveal a requirement for *Bcl11a* in DMBA-induced mammary tumourigenesis.

To investigate *Bcl11a* oncogenic activity in the DMBA model further, we performed the DMBA mutagenesis experiment using *Trp53flox/flox*³⁰ (*p53* single cko) or *Bcl11aflox/flox/p53flox/flox* (cko alleles for both *p53* and *Bcl11a* or *Dflox/flox*) mammary tissues. In the recipients transplanted with *Trp53flox/flox* cells,

Figure 5 | *Bcl11a* is required in DMBA-mediated tumorigenesis. (a) Mouse images and fat pads whole-mount fat pads of either WT, *flox/flox*, *p53^{flox/flox}* or *Dflox/flox* mammary cells. (scale bar, 500 μ m) (b) Quantification of the tumours with DMBA-mediated tumour development from the four depicted groups of engrafted cells over a period of 26 weeks. A log-rank (Mantel-Cox) test was used to compare the two groups and calculate the *P* value. (c) Tumour size quantification of DMBA-mediated tumours in WT, +/-flox and *flox/flox* mice. Mice were checked regularly for tumour development and once detected, Cre activation was induced using three injections of tamoxifen (first day of injection is indicated by black arrow). Tumours size was then monitored for up to 20 days or until they reach a critical size.

palpable tumours were detectable as early as 4 weeks after the last injection of DMBA, and most tumours were detectable by week 10 (Fig. 5b; *n* = 16). However, deletion of *Bcl11a* together with *p53* in *Dflox/flox* mice severely delayed tumour development with only 4 out of 16 mice developing tumours by week 17 (Fig. 5b). This result indicates that BCL11A is a potent oncogene and is required in concert with *p53* for tumour development.

***Bcl11a* is required for the maintenance of DMBA tumours.** Although *Bcl11a* is important for DMBA-induced mammary tumour formation, it is more clinically relevant if it has functions in mammary tumour progression and maintenance. We thus performed the DMBA mutagenesis on WT, *flox/+* and *flox/flox* mammary epithelial cells before the induction of *Bcl11a* deletion. Only when mammary tumours were detected and measured, the mice were then injected with tamoxifen to induce *Bcl11a* deletion. As shown in Fig. 5c, deletion of *Bcl11a* caused a significant reduction in tumour size as soon as 5 days post deletion. On contrary, tumours from the control heterozygous donor cells continued to grow post tamoxifen injection (Fig. 5c). The requirement of *Bcl11a* in the established mouse mammary tumours is consistent with the decreased tumorigenesis of BCL11A knockdown breast cancer cells and underscores its candidature for therapeutic development.

***Bcl11a* is required for mammary stem and progenitor cells.**

To understand the biological function of *Bcl11a* in healthy mammary epithelial cells, we generated a *Bcl11a-lacZ* knock-in mouse to determine the temporal and spatial expression of *Bcl11a* in the mammary gland (Supplementary Fig. 7a). X-gal staining of the reporter embryos revealed that *Bcl11a* was expressed in the mammary placodes from 12.5dpc (Fig. 6a). At puberty, *Bcl11a* was expressed in the cap cells of the terminal end buds, a region thought to harbour stem cells³¹ (Fig. 6b). During adult mammary gland development, *Bcl11a* exhibited a dynamic expression pattern with a marked increase at early gestation and a gradual decline towards lactation and involution (Supplementary Fig. 7b). qRT-PCR analysis of RNA samples from several mammary epithelial compartments^{32,33} detected higher levels of *Bcl11a* expression in the luminal progenitors (CD49b⁺/CD24^{hi}), the basal cells (CD49F^{hi}/CD24⁺) and the mammary stem cell (MaSC) (CD49F^{hi}/CD24^{med})-enriched population (Fig. 6c).

We next induced *Bcl11a* deletion and analysed the mammary epithelial fluorescence-activated cell sorting profile 3 weeks post deletion. The basal mammary epithelial cells from the *flox/flox* mice appeared to be depleted, and in particular the MaSC fraction (Fig. 6d). In addition, *Bcl11a* deletion caused a significant decrease in the number of luminal colony-forming cells (CFCs) (Supplementary Fig. 7c). To functionally demonstrate loss of

Figure 6 | Expression and critical roles of *Bcl11a* in mouse MaSCs and progenitors. (a,b) X-gal staining of a 12.5dpc embryo and whole mount of the mammary gland from a 5-week-old *Bcl11a*-LacZ/+ female virgin mouse. The dashed circles highlight the mammary placodes and the terminal end buds. LN: lymph node. (scale bar, 500 μ m) (c) qRT-PCR for *Bcl11a* in different mammary epithelial cell compartments that were fluorescence-activated cell sorting-purified using antibodies for CD24, CD49f and CD49b. Data are presented as mean $\pm$ s.d. ($n = 3$) and t -test was performed and the P values are displayed on the plot. (d) Depletion of the MaSCs-enriched population (CD24^{med}CD49f^{hi}, dashed lines) in the *Bcl11a*-deficient mammary gland detected by flow cytometric analysis. (e) Limiting dilution transplant (fat pad) assay showing severely compromised engraftment of *Bcl11a*-deficient MaSCs. Stem cell frequency calculation is described in the Methods.

MaSC activities upon *Bcl11a* deletion and to determine that the defects are cell-autonomous, we transplanted control and *flox/flox* cells at limiting dilution into cleared fat pads of NSG mice (see Methods). We found approximately sixfold reduction in stem cell frequency from 1/483 to 1/2859, in the *Bcl11a*-deficient mammary gland (Fig. 6e). Reduction of MaSCs and progenitors in the *Bcl11a*-deficient mammary gland was also reflected in the altered expression of the MaSC gene expression signature³⁴ (Supplementary Table 1) (Supplementary Fig. 7e).

Discussion

We have demonstrated here that the transcription regulator BCL11A is a novel breast cancer gene. By investigating cancer genomics data from ~3,000 patients (METABRIC and TCGA), BCL11A was significantly expressed at higher levels in TNBC and particularly in BLBC/IC10 tumours both at RNA and protein levels. Experimentally, we have shown that disrupting BCL11A expression in TNBC cell lines and in the mouse significantly reduced tumour development and maintenance. At the cellular level, *Bcl11a* is expressed and required in both MaSCs and luminal progenitor cells in the mammary gland. Lineage tracing experiments in the future will determine if *Bcl11a* is expressed in the recently identified lineage-restricted luminal and basal progenitor cells³⁵ or in the bipotent MaSCs³⁶. Importantly, given the recent implication of luminal progenitors as the ‘cell of origin’ of BLBC^{37,38}, it will be important to ascertain if *Bcl11a*

upregulation in luminal progenitor cells is one of the earliest steps in TNBC development.

In addition, it will be important to identify how BCL11A is transcriptionally regulated and what are its downstream targets in TNBC. In erythrocytes, KLF1 has been shown to affect BCL11A expression³⁹, while in non-small cell lung cancer MIR30A has been suggested to regulate BCL11A expression⁴⁰. We found no correlation between KLF1 or MIR30A and BCL11A expression in the TCGA data set (Supplementary Fig. 8), suggesting that BCL11A regulation could be context dependent. In terms of downstream targets, in leukaemia, it has been shown that BCL11A abrogates p21 transcription possibly via direct regulation of SIRT1 (refs 41,42). Previous work from our lab also showed that in B cells, BCL11A induces MDM2 expression, which is a negative regulator of p53 (ref. 43). However, the TCGA data does not indicate a strong correlation between BCL11A and SIRT1 or MDM2 expression at least in the tumour context (Supplementary Fig. 8). Therefore, identifying the putative BCL11A regulators and its downstream targets in the breast epithelial cells should clarify its molecular and cellular roles in TNBC.

In conclusion, through cancer genomics, *in vitro* assays, experimental xenograft models and mouse genetics, we have demonstrated in this study that BCL11A is a new breast cancer gene and a critical regulator in normal mammary epithelial development. These results warrant further investigation of BCL11A as a potential candidate for TNBC-targeted therapy.

Methods

Mouse strains and breeding. All experimental animal work was performed in accordance to the Animals (Scientific Procedures) Act 1986, UK and approved by the Ethics Committee at the Sanger Institute. *Bcl11a* bacterial artificial chromosomes (BACs) were identified from the 129/SvJ mouse BAC library (Sanger Institute) and used to generate the *Bcl11a-lacZ*- and *Bcl11a* cko-targeting vectors. For *Bcl11a-lacZ* reporter, targeting construct (Supplementary Fig. 7a) was generated based on the recently published strategy⁴⁴. For the *Bcl11a* cko mouse, targeting construct (Supplementary Fig. 6a) was generated based on the original recombineering strategy⁴⁵. Gene targeting in embryonic stem (ES) cells and chimera production were performed according to the standard procedures. The *Bcl11a* cko line was then crossed to the Rosa26-Cre-ERT2 mouse line described previously⁴⁶. The *p53* cko line was described previously³⁰. Homozygous *p53* cko mice were crossed to the *Bcl11a*/Cre-ERT2 line described above and the F1 generation was mated to generate mice doubly conditional for *Bcl11a* and *p53*. Genotyping was confirmed using the primers listed in Supplementary Table 2. Cre activation was mediated by three injections of 1 mg tamoxifen per mouse over 3 days.

Mammary epithelial cell isolation and analysis. Mammary epithelial cells were dissociated using a mixture of collagenase (Roche) and hyaluronidase (Sigma), and cells were stained using the following primary antibodies: biotinylated anti-CD45 (clone 30-F11; eBioscience, 1:500), anti-Ter119 (clone Ter119; eBioscience, 1:500) and anti-CD31 (clone 390; eBioscience, 1:500); anti-CD24-R-phycoerythrin (PE; clone M1/69, eBioscience, 1:500), anti-CD49f-Alexa Fluor 647 (AF647; clone GoH3, eBioscience, 1:100), anti-CD49b-Alexa Fluor 488 (AF488; clone Hma2; eBioscience, 1:500) and Sca1-Alexa Fluor 647 (AF647; clone D7, eBioscience, 1:500). Secondary antibodies used: Streptavidin-PE-Texas Red (PE-TR; Molecular Probes, 1:500). Apoptotic cells were excluded by elimination of propidium iodide-positive cells. Flow cytometric analysis was done using CyAn ADP (DakoCytomation) and all sorts were performed using MoFlo (DakoCytomation) and gates were set to exclude >99.9% of cells labelled with isoform-matched control antibodies conjugated with the corresponding fluorochromes. For whole-mount analysis, abdominal glands (no. 4) were spread out using forceps on a glass slide and incubated in Carnoy's fixative overnight. The slide was washed in water and placed in carmine alum (Sigma) stain overnight. The slide was again washed with ethanol and cleared in Xylene for 1 day before documentation. For histological analysis, abdominal glands were fixed in 4% formaldehyde in PBS for 24 h at room temperature. The glands were transferred to 70% ethanol and stored at -20°C until embedding and sectioning. All tissues were embedded in wax and sectioned at 5 μm before being stained with haematoxylin and eosin.

Mammary CFC assay. For colony-forming assays, the medium used was (human) NeuroCult NS-A Proliferation Medium (StemCell) supplemented with 5% fetal bovine serum, 10 ng ml^{-1} epidermal growth factor (Sigma), 10 ng ml^{-1} basic fibroblast growth factor (Peprotech) and N2 Supplement (Invitrogen); the cultures were maintained at $37^{\circ}\text{C}/5\%\text{ CO}_2$ for 7 days; then fixed using ice-cold acetone/methanol (1:1) and visualized using Giemsa staining (Merck). Lin[−]CD24^{hi}CD49b⁺ luminal progenitors from the *flox/flox* mammary gland were sorted and plated with irradiated feeders in colony-forming assay medium for 6 days before the number of mammary CFCs was enumerated.

Transplantation of mammary epithelium. Mammary epithelial cells (basal fraction) from tamoxifen-injected and non-injected *flox/flox* or *flox/+* mice were sorted based on CD24/CD49f and transplanted in limiting doses (500/750/1,000/2,000 cells) into cleared fat pads of 3-week-old NSG females. In each case, non-injected and tamoxifen-injected epithelial cells were engrafted into contralateral glands of the same recipient mice. The recipient mice were impregnated 3–6 weeks after transplant and outgrowths produced were dissected, stained with carmine and scored. Stem cell frequency was calculated using L-Calc (StemCell Technologies).

DMBA/MPA tumorigenesis protocol. Mammary fragments were transplanted into cleared fat pads of 3-week-old NSG mice. At the time of surgery, the MPA slow release pellet (Innovative Research of America) was also implanted subcutaneously. The mice were allowed to recover for 2 weeks and then *Bcl11a* deletion was induced using three injections of tamoxifen. One week after deletion of *Bcl11a*, 1 mg of DMBA (Sigma) was administered orally; this was followed by three further doses of 1 mg of DMBA over 3 weeks. Mice were then examined weekly for tumour incidence and killed when tumours reached the legal limit.

Transfection and mammosphere assays. EpH4 (gift from Professor Christine Watson) and MDA231 (ATCC) cells were cultured to confluence in 1:1 DMEM:F12 (Invitrogen) media containing 10% fetal calf serum (FCS; FetalcloneIII, Clontech). 4T1 (ATCC) cells were cultured in Roswell Park Memorial Institute (RPMI) media (Invitrogen) containing 10% FCS, and SUM159 cells (gift from Dr Charlotte Kuperwasser) were cultured in Ham's F12 (Sigma), 5% FCS, insulin ($5\text{ }\mu\text{g ml}^{-1}$, Sigma) hydrocortisone ($1\text{ }\mu\text{g ml}^{-1}$, Sigma) and $1\times$ Penicillin Streptomycin Glutamine (PSG) (Gibco). HMLE and HMLER cells (gift from Professor Robert Weinberg)

were cultured in complete HuMEC media (Invitrogen). The control or the *Bcl11a* overexpression piggyBac vectors were delivered into cells using the Amaxa Basic Nucleofactor Kit for primary mammalian epithelial cells (Lonza) according to the manufacturer's recommendations. Transfected cells were maintained at $37^{\circ}\text{C}/5\%\text{ CO}_2$ for 48 h. Cells were then cultured in puromycin ($1\text{--}5\text{ }\mu\text{g ml}^{-1}$) for 48 h to allow for selection. To induce BCL11A expression in EpH4 and HMLE cells, doxycycline (Clontech) was used at a final concentration of $1.0\text{ }\mu\text{g ml}^{-1}$. Floating or Matrigel-embedded mammosphere were cultured and passaged as previously described⁴⁷ in ultra-low attachment plates (Corning).

RNA knockdown. *BCL11A* shRNA sequences were obtained from the TRC consortium⁴⁸ (TRCN0000033449 and TRCN0000033453) were cloned into piggyBac transposon vector (PB-H1-shRNA-GFP). 4T1, SUM159, MDA231 and HMLER cells were transfected with $4.0\text{ }\mu\text{g}$ of piggyBac vector using Amaxa Basic Nucleofactor Kit for primary mammalian epithelial cells (Lonza) and GFP⁺ cells were sorted/analysed 24–48 h later.

RNA extraction and real-time PCR analysis. RNA from sorted cells was extracted using PicoPure RNA isolation kit (Molecular Devices) according to the manufacturer's instructions. RNA from mammary tissue and cell lines was extracted using Tri-Reagent (Invitrogen) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from 1 to $2\text{ }\mu\text{g}$ of total RNA using the Transcriptor Reverse Transcription cDNA Synthesis Kit (Roche). RT-PCR was performed using Hi-Fidelity Extensor mix (Thermo) using primers listed in Supplementary Table 2. Quantitative real-time PCR detection of cDNA was performed using SYBR Green Master Mix (Sigma, ABI and Invitrogen) according to supplier's recommendations. The real-time PCR reactions were run in ABI-7900HT (Applied Biosystems) in triplicate. Primers used for real-time PCR on mouse samples were designed using PrimerBank⁴⁹ website (<http://pga.mgh.harvard.edu/primerbank/>) and listed in Supplementary Table 2. All primers were purchased from Sigma-Aldrich. For real-time PCR on human samples Taqman gene expression probes (Life Technologies) were used.

Cell cycle analysis. A total of 150,000 control or *BCL11A* knockdown cells were seeded in six-well plates and allowed to recover for 48 h. Cells were then incubated with $5\text{ }\mu\text{M}$ Edu (Invitrogen) for 1 h. Cells were fixed and assayed using the Edu flow cytometry detection kit (Invitrogen) following the manufacturer's instructions.

Annexin v assays. A total of 100,000 control or *BCL11A* knockdown cells (in triplicates) were seeded in six-well plates and allowed to recover for 48 h. Cell were then collected and stained using the Annexin-V-AF647 (BioLegend) following the manufacturer's instructions, and cells were then quantified using fluorescence-activated cell sorting.

Cell viability assay. A total of 1,000 control or *BCL11A* knockdown cells (in triplicates) were seeded in 96-well plates and allowed to recover for 48 h. Cells were then incubated with CellTiter Aqueous One Solution (Promega) for 4 h following the manufacturer's instructions. Absorbance was then measured at 490 nm using a plate reader (Bio-Rad).

Western blotting and IHC. Protein samples were prepared as described previously¹⁴ and probed using anti-Bcl11a (Abcam, Clone 14B5, 1:1000) and Actin (Cell Signalling, 1:10000). For IHC analysis, BCL11A (Abcam (14B5, 1:50); CK14 (Abcam; 1:100) and ER α (SCBT; 1:50) were used. Staining was detected using AF488- or Cy3-conjugated secondary (Sigma) and bisbenzimidazole-Hoechst 33342 (Sigma). Fluorescence microscopy was carried out using a Zeiss Axiophot microscope equipped with a Hamamatsu Orca 285 camera, with images visualized, captured and manipulated using Simple PCI 6 (C Imaging Systems). The haematoxylin- and eosin-stained samples were visualized on a LEICA light microscope, while the mouse mammary gland whole mounts were visualized using the LEICA MZ75 light microscope.

Microarray analysis. The intensity value for each probe set was calculated and the average of each gene was computed before the data analysis. For the quality control (QC) step, a set of intensity value of control genes were examined. All data were normalized and scaled by Partek Genomic Suite 6.4. Principal components analysis was performed to show the distribution of samples, eliminating outliers. Differentially expressed genes were selected by one-way analysis of variance by the factor of KO versus wild type, P value < 0.08. Hierarchical clustering of selected genes was performed to show the expression pattern. The resulting genes then underwent a pathway analysis (GeneGO: <http://www.genego.com>) to determine the biological significance of the data.

Xenograft tumorigenesis assays. One hundred thousand EpH4, HMLE, 4T1, MDA231, SUM159 or HMLER cells were suspended in 25% Matrigel (BD

Biosciences) and HBSS, and injected into either cleared contralateral number 4 mammary fat pads of 3-week-old female mice or subcutaneously in 6–12-week-old female NSG mice. For secondary transplants, tumours were dissociated using collagenase/hyaluronase mix (Roche) for 16 h and viable cells were counted and injected into NSG recipient mice at the indicated doses.

METABRIC analysis. Matched DNA and RNA were extracted for tumours. CN analysis was performed using the Affymetrix SNP 6.0 platform. The arrays were pre-processed and normalized using CRMAv2 (ref. 50) method from aroma.affymetrix. Allelic-crosstalk calibration, probe sequence effects normalization, probe-level summarization and PCR fragment length normalization were performed for each array. The intensities obtained were normalized against a pool of 473 normals for the samples with no matched pair or against their matched normal when available (258 samples). The log-ratios were then segmented using the circular binary segmentation algorithm⁵¹ in the DNACopy Bioconductor package⁵². Then, callings into five groups (homozygous deletion, heterozygous deletion, neutral CN, gain (>2) and amplification (>3)) were made using thresholds based on the variability of each sample and their proportion of tumoural cells. RNA analysis was performed using Illumina HT-12 v3 platform and analysed using beadarray package⁵³. BASH⁵⁴ was used to correct for spatial artifacts. The bead-level data were summarized and a selection of suitable probes based on their quality was done using the re-annotation of the Illumina HT-12v3 platform⁵⁵. The samples were classified into the five breast cancer subtypes using PAM50 (ref. 56), but only those genes with a probe with perfect annotation on the chip were considered. A mixture model was used to classify BCL11A expression into low and high values^{57,58}.

TCGA data analysis. All TCGA data and figures were accessed, analysed and generated using the cBio Cancer Genomics Portal⁵⁹. All data included in this manuscript is in agreement with the TCGA publication guidelines.

METABRIC IHC analysis. A subset of patients enrolled in the METABRIC study with tumour samples represented in tissue microarrays (TMAs) were included for the detection of BCL11A protein expression by IHC. TMAs were constructed from formalin-fixed paraffin-embedded tumour blocks as previously described⁶⁰. Each tumour was represented by a single 0.6-mm tissue core. A total of 439 tumours were included arising from 436 patients (three were synchronous tumours arising in the contralateral breast). CN and gene expression data was available for 368 of these tumours for correlative analyses. Three micrometre TMA sections were dewaxed in xylene and rehydrated through graded alcohols. IHC was conducted using a BondMax Autoimmunostainer (Leica, Bucks, UK). Antigen retrieval was achieved by heating TMA sections in pH 6 citrate buffer for 20 min. Primary mouse monoclonal (clone 14B5) antibody bound to BCL11A (ab19487, AbCam) was diluted to 1:200 and detected using a BOND Polymer detection kit (Leica) and signal developed with 3,3'-diaminobenzidine (DAB). Stained TMA sections were digitized using the Ariol (Genetix Ltd, Hampshire, UK) platform for scoring by a pathologist (H.R.A.). The ordinal Allred scoring system was used for assessing the amount of staining present in tumour cells accounting for the intensity (0 = no staining, 1 = weak, 2 = moderate and 3 = strong) and proportion (0 = 0%, 1 = $<1\%$, 2 = 1–10%, 3 = 11–33%, 4 = 34–66% and 5 = $>66\%$) of stained cells, finally producing a summed score (intensity + proportion = Allred score) between zero and eight. Analogous to clinical practice for estrogen receptor (ER), tumours with an Allred score of >2 were deemed positive for BCL11A expression and comparison with molecular subtypes was made using Pearson's χ^2 test.

Statistical significance. All *P* values were calculated using Student's *t*-test unless otherwise indicated in the figure legends.

References

- Blows, F. M. *et al.* Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med.* **7**, e1000279 (2010).
- Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. *N. Engl. J. Med.* **363**, 1938–1948 (2011).
- Perou, C. M. *et al.* Molecular portraits of human breast tumours. *Nature* **406**, 747–752 (2000).
- Carey, L., Winer, E., Viale, G., Cameron, D. & Gianni, L. Triple-negative breast cancer: disease entity or title of convenience? *Nat. Rev. Clin. Oncol.* **7**, 683–692 (2010).
- Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**, 346–352 (2012).
- Prat, A. *et al.* Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res.* **12**, R68 (2010).
- Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. *J. Pathol.* **220**, 263–280 (2010).
- TCGA. Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61–70 (2012).
- Shah, S. P. *et al.* The clonal and mutational evolution spectrum of primary triple-negative breast cancers. *Nature* **486**, 395–399 (2012).
- Stingl, J. & Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. *Nat. Rev. Cancer* **7**, 791–799 (2007).
- Bouras, T. *et al.* Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. *Cell Stem Cell* **3**, 429–441 (2008).
- Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D. & Werb, Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. *Cell* **127**, 1041–1055 (2006).
- Asselin-Labat, M. L. *et al.* Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. *Nat. Cell Biol.* **9**, 201–209 (2007).
- Khaled, W. T. *et al.* The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. *Development* **134**, 2739–2750 (2007).
- Zuo, T. *et al.* FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. *Cell* **129**, 1275–1286 (2007).
- Mehra, R. *et al.* Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. *Cancer Res.* **65**, 11259–11264 (2005).
- Desmedt, C. *et al.* Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. *Clin. Cancer Res.* **13**, 3207–3214 (2007).
- Hatzis, C. *et al.* A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* **305**, 1873–1881 (2011).
- Ma, X. J. *et al.* A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. *Cancer Cell* **5**, 607–616 (2004).
- Schmidt, M. *et al.* The humoral immune system has a key prognostic impact in node-negative breast cancer. *Cancer Res.* **68**, 5405–5413 (2008).
- Weniger, M. A. *et al.* Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma. *Leukemia* **20**, 1880–1882 (2006).
- Nakamura, T. *et al.* Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product. *Mol. Cell Biol.* **20**, 3178–3186 (2000).
- Reichmann, E., Ball, R., Groner, B. & Friis, R. R. New mammary epithelial and fibroblastic cell clones in coculture form structures competent to differentiate functionally. *J. Cell Biol.* **108**, 1127–1138 (1989).
- Ince, T. A. *et al.* Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. *Cancer Cell* **12**, 160–170 (2007).
- Elenbaas, B. *et al.* Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. *Genes Dev.* **15**, 50–65 (2001).
- Ishikawa, F. *et al.* Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. *Blood* **106**, 1565–1573 (2005).
- Liu, P. *et al.* Bcl11a is essential for normal lymphoid development. *Nat. Immunol.* **4**, 525–532 (2003).
- Herschkowitz, J. I. *et al.* Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol.* **8**, R76 (2007).
- Herschkowitz, J. I. *et al.* Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. *Proc. Natl Acad. Sci. USA* **109**, 2778–2783 (2012).
- Jonkers, J. *et al.* Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nat. Genet.* **29**, 418–425 (2001).
- Hennighausen, L. & Robinson, G. W. Information networks in the mammary gland. *Nat. Rev. Mol. Cell Biol.* **6**, 715–725 (2005).
- Stingl, J. *et al.* Purification and unique properties of mammary epithelial stem cells. *Nature* **439**, 993–997 (2006).
- Shackleton, M. *et al.* Generation of a functional mammary gland from a single stem cell. *Nature* **439**, 84–88 (2006).
- Lim, E. *et al.* Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. *Breast Cancer Res.* **12**, R21 (2010).
- Van Keymeulen, A. *et al.* Distinct stem cells contribute to mammary gland development and maintenance. *Nature* **479**, 189–193 (2011).
- Rios, A. C., Fu, N. Y., Lindeman, G. J. & Visvader, J. E. *In situ* identification of bipotent stem cells in the mammary gland. *Nature* **506**, 322–327 (2014).
- Lim, E. *et al.* Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. *Nat. Med.* **15**, 907–913 (2009).
- Molyneux, G. *et al.* BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. *Cell Stem Cell* **7**, 403–417 (2010).

39. Zhou, D., Liu, K., Sun, C. W., Pawlik, K. M. & Townes, T. M. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. *Nat. Genet.* **42**, 742–744 (2010).
40. Jiang, B. Y. *et al.* BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. *Mol. Cancer* **12**, 61 (2013).
41. Senawong, T., Peterson, V. J. & Leid, M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. *Arch. Biochem. Biophys.* **434**, 316–325 (2005).
42. Yin, B. *et al.* A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. *Blood* **113**, 1075–1085 (2008).
43. Yu, Y. *et al.* Bcl11a is essential for lymphoid development and negatively regulates p53. *J. Exp. Med.* **209**, 2467–2483 (2012).
44. Chan, W. *et al.* A recombineering based approach for high-throughput conditional knockout targeting vector construction. *Nucleic Acids Res.* **35**, e64 (2007).
45. Liu, P., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineering-based method for generating conditional knockout mutations. *Genome Res.* **13**, 476–484 (2003).
46. Hameyer, D. *et al.* Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. *Physiol. Genomics* **31**, 32–41 (2007).
47. Dontu, G. *et al.* In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. *Genes Dev.* **17**, 1253–1270 (2003).
48. Moffat, J. *et al.* A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* **124**, 1283–1298 (2006).
49. Wang, X. & Seed, B. A PCR primer bank for quantitative gene expression analysis. *Nucleic Acids Res.* **31**, e154 (2003).
50. Bengtsson, H., Wirapati, P. & Speed, T. P. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. *Bioinformatics* **25**, 2149–2156 (2009).
51. Venkatraman, E. S. & Olshen, A. B. A faster circular binary segmentation algorithm for the analysis of array CGH data. *Bioinformatics* **23**, 657–663 (2007).
52. Seshan VE, O. A. DNACopy: DNA copy number data analysis R package <http://www.bioconductor.org/packages/2.3/bioc/html/DNACopy.html> (2010).
53. Dunning, M. J., Smith, M. L., Ritchie, M. E. & Tavaré, S. beadarray: R classes and methods for Illumina bead-based data. *Bioinformatics* **23**, 2183–2184 (2007).
54. Cairns, J. M., Dunning, M. J., Ritchie, M. E., Russell, R. & Lynch, A. G. BASH: a tool for managing BeadArray spatial artefacts. *Bioinformatics* **24**, 2921–2922 (2008).
55. Barbosa-Morais, N. L. *et al.* A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. *Nucleic Acids Res.* **38**, e17.
56. Parker, J. S. *et al.* Supervised risk predictor of breast cancer based on intrinsic subtypes. *J. Clin. Oncol.* **27**, 1160–1167 (2009).
57. Yeung, K. Y., Fraley, C., Murua, A., Raftery, A. E. & Ruzzo, W. L. Model-based clustering and data transformations for gene expression data. *Bioinformatics* **17**, 977–987 (2001).
58. Fraley, C. & Raftery, A. E. MCLUST Version 3 for R: Normal Mixture Modeling and Model-based Clustering. Technical Report No. 504, Department of Statistics, University of Washington (2006).
59. Cerami, E. *et al.* The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2**, 401–404 (2012).
60. Kononen, J. *et al.* Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat. Med.* **4**, 844–847 (1998).

Acknowledgements

W.T.K., S.C.L. and J.W. were funded by the Sanger Institute. W.T.K. was also funded by a BBSRC project grant and a Junior Research Fellowship, King's College, Cambridge and a Cancer Research UK Career establishment award. J.S. is funded by Cancer Research UK, The University of Cambridge and Hutchison Whampoa Limited. C.J.W. is funded by BBSRC, MRC and BCC. We would like to thank Dr Floris Fojier and Professor Allan Bradley for providing the p53 kco mice. We thank Dr Shannon Burke, Dr Sara Pensa and Lauma Skruzmane for comments on the manuscript. We thank Miss Malgorzata Gawedzka from the W.T.K. lab for the technical assistance. We thank the Sanger Institute RSF, the flow cytometry core and microarray facilities for the technical assistance. This work is supported by Wellcome Trust (Grant number—098051) (P.L.).

Author contributions

W.T.K. performed the mouse tumour studies, the cell culture experiments and analysed the *Bcl11a* kco line. S.C.L. generated and analysed the *Bcl11a-LacZ* mouse line and the *Bcl11a* kco line. J.S. developed the flow-sorting strategies, performed some of the colony assays, designed and performed some of the fat pad transplantation experiments. X.C. performed the microarray analysis. O.M.R., H.R.A., S.-F.C., S.A. and C.C. analysed and provided all the data (CN, expression, qRT-PCR and IHC) from the METABRIC cohort. All enquiries relating to the METABRIC data set should be made directly to carlos.caldas@cancer.org.uk. J.W. assisted with mouse experiments. Y.Y. assisted with qRT-PCR and cloning of shRNA constructs. A.F. and M.S. provided the reagents. The *Bcl11a* kco allele was made by P.L. in laboratory of N.G.C. and N.A.J. C.J.W. provided the reagents and contributed to the design of the study. W.T.K., S.C.L. and P.L. designed the studies and wrote the manuscript. The overall research project and manuscript writing are supervised by P.L.

Additional information

Accession codes: Microarray data have been deposited in the Gene Expression Omnibus database with the accession number GSE63386.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Khaled, W.T. *et al.* BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. *Nat. Commun.* 6:5987 doi: 10.1038/ncomms6987 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>